TJPC(SH:600488) Zhong Guo Zhi Liang Xin Wen Wang·2025-06-13 14:31Group 1 - The company involved is Tianjin Pharmaceutical Co., Ltd., which is engaged in the production of pharmaceuticals, veterinary drugs, cosmetics, and food additives [1][2] - The company and its representatives are accused of violating the Anti-Monopoly Law by engaging in monopolistic behavior with competitors [2][3] - The investigation was initiated based on a tip-off from the State Administration for Market Regulation, leading to a formal inquiry into the company's practices [2][3] Group 2 - The primary product involved is Dexamethasone Sodium Phosphate, a key raw material for producing Dexamethasone injection, which is used for treating various inflammatory diseases and has been included in COVID-19 treatment protocols [4][6] - The company, along with three other competitors, was found to have a direct competitive relationship in the production and sale of this raw material [6][7] Group 3 - Evidence indicates that the company participated in a price-fixing agreement for Dexamethasone Sodium Phosphate, which included a meeting on November 20, 2021, to discuss price increases and the cessation of price competition [7][8] - The company raised the price of Dexamethasone Sodium Phosphate from 9,000 yuan per kilogram to 13,800 yuan per kilogram in February 2022, following the agreement [7][9] Group 4 - The company reported illegal earnings of 42,764,400 yuan from the price-fixing activities [9] - Following the investigation, the company applied for leniency and began to lower prices in June 2024, indicating a willingness to rectify its actions [10][13] Group 5 - The administrative penalties imposed include the confiscation of illegal earnings and a fine based on the company's sales revenue, with a total penalty amounting to 69,192,350.36 yuan [13][14] - The company's general manager, Liu Xin, was also fined 600,000 yuan for personal responsibility in the monopolistic practices [15]